Objective: To compare MIDP with ODP regarding radical resection rate for pancreatic ductal adenocarcinoma (PDAC) in the pancreatic body or tail. Study design: A pan-European, randomized controlled, multicenter, patient-blinded non-inferiority trial. This protocol was designed according to the SPIRIT guidelines1. Pathologists judging the primary endpoint will be blinded for the surgical approach (MIDP vs ODP). A blinded adjudication committee will assess all endpoints. Study population: Two groups of 129 patients (258 in total) with an indication for elective distal pancreatectomy with splenectomy because of proven or highly suspected PDAC. Intervention: Minimally invasive distal pancreatectomy (either laparoscopic or robot-assisted) Control: Open distal pancreatectomy
Rationale: Several systematic reviews have suggested superior short term outcomes after minimally invasive distal pancreatectomy (MIDP) as compared to open distal pancreatectomy (ODP) for benign and pre-malignant disease. In the literature and in a recent pan-European survey, about one third of pancreatic surgeons expressed concerns regarding the oncologic safety (i.e. radical resection, lymph node retrieval and survival) of MIDP in pancreatic cancer. Most surgeons stated that a randomized trial assessing oncologic safety in MIDP vs ODP for pancreatic cancer is needed. Objective: To compare MIDP with ODP regarding radical resection rate for pancreatic ductal adenocarcinoma (PDAC) in the pancreatic body or tail. Study design: A pan-European, randomized controlled, multicenter, patient-blinded non-inferiority trial. This protocol was designed according to the SPIRIT guidelines1. Pathologists judging the primary endpoint will be blinded for the surgical approach (MIDP vs ODP). A blinded adjudication committee will assess all endpoints. Study population: Two groups of 129 patients (258 in total) with an indication for elective distal pancreatectomy with splenectomy because of proven or highly suspected PDAC. Intervention: Minimally invasive distal pancreatectomy (either laparoscopic or robot-assisted) Control: Open distal pancreatectomy Main study parameters/endpoints: Primary outcome is the microscopically radical (R0, \>1mm) resection rate. Main secondary outcomes are survival, lymph node retrieval, intraoperative outcomes (such as blood loss, operative time and conversion), postoperative outcomes (such as complications, time to functional recovery and hospital stay) and quality of life
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Enrollment
9
Minimally invasive distal pancreatectomy (either laparoscopic or robot-assisted)
open distal pancreatectomy
Hôpital Beaujon - APHP
Clichy, France
CHU Saint Eloi - Montpellier
Montpellier, France
Centre Hospitalier Orléans
Orléans, France
Institut Mutualiste Montsouris
Paris, France
Hôpital Paul Brousse
Villejuif, France
microscopically radical resection rate
R0, \>1mm
Time frame: 1 day
survival
Date of death
Time frame: 1 year
survival
Date of death
Time frame: 2 years
survival
Date of death
Time frame: 3 years
lymph node retrieval
Tumor positive lymph nodes retrieved
Time frame: 1 day
Operative time
Operative time from first incision to closure of the abdomen, minutes
Time frame: 1 day
Intraoperative blood loss
Intraoperative blood loss, mL (suction canister and weight of gauzes)
Time frame: 1 day
intraoperative outcomes
Total duration of the procedure, minutes
Time frame: 1 day
postoperative outcomes
Major complications
Time frame: 1 day
specimen size
Tumor size, mm
Time frame: 1 day
Specimen length
Specimen length, mm
Time frame: 1 day
margin
Distance from tumor to transection, anterior and posterior margin, mm
Time frame: 1 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.